

Drug Utilization Review Board (DURB) Agenda

April 26, 2024 – 9:00 am

Texas Health and Human Services Commission (HHSC), John H. Winters Building, Public Hearing Room 125, 1st Floor
701 West 51st Street, Austin, TX
78751

[Webcasting Available \[/about/meetings\]](#)

This meeting will be webcast. Members of the public may attend the meeting in person at the address above or access a live stream of the meeting at <https://texashhsmeetings.org/HHSWebcast> [\[/about/live-archived-meetings\]](#) . Select the tab for the Winters Live on the date and time for this meeting. Please e-mail Webcasting@hhsc.state.tx.us [\[mailto:Webcasting@hhsc.state.tx.us\]](mailto:Webcasting@hhsc.state.tx.us) if you have any problems with the webcasting function.

This meeting will also be conducted via videoconference call in accordance with the requirements of Section 551.127, Government Code. The member of the Board presiding over the meeting will be physically present at the location specified above.

Attendees who would like to provide public comment should see the **Public Comment** section below.

1. Call to order
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws
3. Consideration of January 26, 2024, draft meeting minutes
4. Reconsideration of October 13, 2023, draft revised meeting minutes, limited to correcting the vote determination for agenda item 4j
5. House Bill 3286, 88th Texas Legislature, Regular Session (2023), update
6. [Open Meetings Act overview \[/sites/default/files/documents/apr-2024-durb-agenda-item6.pdf\]](#)
7. Public comment and discussion on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
 - a. Anti-allergens, oral
 - b. Antibiotics, inhaled
 - c. Anticoagulants
 - d. Antidepressants, other
 - e. Antidepressants, selective serotonin reuptake inhibitors
 - f. Antidepressants, tricyclic
 - g. Antihyperuricemics
 - h. Antivirals (oral/nasal)
 - i. Anxiolytics
 - j. Beta blockers (oral)
 - k. Bile salts
 - l. Benign prostatic hyperplasia agents
 - m. Bronchodilators, beta agonist
 - n. Chronic obstructive pulmonary disease agents
 - o. Cough and cold, cold
 - p. Cough and cold, narcotic
 - q. Cough and cold, non-narcotic
 - r. Cytokine and cell-adhesion molecule antagonists
 - s. Erythropoiesis stimulating proteins
 - t. Hemophilia treatment
 - u. Hereditary angioedema treatments
 - v. Immune globulins
 - w. Immunomodulators, asthma

- x. Immunomodulators, atopic dermatitis
- y. Lincosamides/oxazolidinones/streptogramins
- z. Lipotropics, other
- aa. Lipotropics, statins
- bb. Multiple sclerosis agents
- cc. Pediatric vitamin preparations
- dd. Prenatal vitamins
- ee. Sedative hypnotics
- ff. Sick cell anemia treatments
- gg. Thrombopoiesis stimulating proteins
- hh. Urea cycle disorder, oral

8. Public comment and discussion on single new drugs to be reviewed for the Medicaid PDL:

- a. [Likmez/ antibiotics, gastrointestinal \[/sites/default/files/documents/apr-2024-durb-agenda-item8a.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item8a.pdf)
- b. [Vevye / ophthalmics, anti-inflammatory/immunomodulator \[/sites/default/files/documents/apr-2024-durb-agenda-item8b.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item8b.pdf)
- c. [Iwilfin / oral oncology, other \[/sites/default/files/documents/apr-2024-durb-agenda-item8c.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item8c.pdf)
- d. [Ogsiveo / oral oncology, other \[/sites/default/files/documents/apr-2024-durb-agenda-item8d.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item8d.pdf)
- e. [Velsipity / ulcerative colitis \[/sites/default/files/documents/apr-2024-durb-agenda-item8e.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item8e.pdf)

9. Therapeutic and clinical drug reviews and updates: Gainwell Technologies

10. Executive work session

Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under public comment on the drug classes to be reviewed for the Medicaid PDL, and as permitted by the Texas Open Meetings Act.

11. Announcements of drugs recommended for the Medicaid PDL: Gainwell Technologies

12. [Retrospective drug utilization review \(DUR\): Acentra Health \[/sites/default/files/documents/apr-2024-durb-agenda-item12.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item12.pdf)

a. Potential retro DUR interventions

- i. [Asthma management \[/sites/default/files/documents/apr-2024-durb-agenda-item12ai.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item12ai.pdf)
- ii. [Gabapentinoids drug use evaluation \[/sites/default/files/documents/apr-2024-durb-agenda-item12aii.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item12aii.pdf)
- iii. [Psychotropic polypharmacy \[/sites/default/files/documents/apr-2024-durb-agenda-item12aiii.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item12aiii.pdf)
- iv. [Support Act criteria \[/sites/default/files/documents/apr-2024-durb-agenda-item12aiv.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item12aiv.pdf)

13. [Prospective prior authorization proposals: Acentra Health \[/sites/default/files/documents/apr-2024-durb-agenda-item13.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item13.pdf)

a. [Appetite suppressant agents – new criteria \[/sites/default/files/documents/apr-2024-durb-agenda-item13a.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item13a.pdf) a

i. Phendimetrazine/phentermine

b. [Sphingosine 1-phosphate \(S1P\) receptor modulators – new criteria \[/sites/default/files/documents/apr-2024-durb-agenda-item13b.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item13b.pdf)

i. Velsipity

c. [Vesicular monoamine transporter, type 2 inhibitors \[/sites/default/files/documents/apr-2024-durb-agenda-item13c.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item13c.pdf)

i. Revision

14. [Retrospective drug use criteria for outpatient use in Vendor Drug Program: \[/sites/default/files/documents/apr-2024-durb-agenda-item14.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14.pdf)

[The University of Texas at Austin College of Pharmacy \[/sites/default/files/documents/apr-2024-durb-agenda-item14.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14.pdf)

a. [Benzodiazepines \(oral, nasal, rectal\) \[/sites/default/files/documents/apr-2024-durb-agenda-item14a.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14a.pdf)

- b. [Complement inhibitor and enzyme/ protein replacement therapy \[/sites/default/files/documents/apr-2024-durb-agenda-item14b.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14b.pdf)
- c. [Direct oral anticoagulants \[/sites/default/files/documents/apr-2024-durb-agenda-item14c.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14c.pdf)
- d. [Hydroxy-methylglutaryl coenzyme-A reductase inhibitors \(statins\) \[/sites/default/files/documents/apr-2024-durb-agenda-item14d.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14d.pdf)
- e. [Low molecular weight heparins \[/sites/default/files/documents/apr-2024-durb-agenda-item14e.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14e.pdf)
- f. [Nebulized bronchodilators \[/sites/default/files/documents/apr-2024-durb-agenda-item14f.pdf\]](/sites/default/files/documents/apr-2024-durb-agenda-item14f.pdf)

15. Review of action items for next meeting: July 26, 2024, 9:00 a.m.

16. Adjourn

The board may take action on any agenda item.

Public Comment: HHSC welcomes public comments pertaining to topics related to DURB and Medicaid PDL. Members of the public who would like to provide public comment may choose from the following options:

1. **Oral comments provided virtually:** Members of the public **must** pre-register to provide oral comments virtually during the meeting by completing a Public Comment Registration form at https://texashhsm meetings.org/DURB_PCReg_Apr2024 [https://texashhsm meetings.org/DURB_PCReg_Apr2024] and submitting a completed Public Comment Form, HHS Form 1320 at <https://www.txvendordrug.com/advisory/dur-board-documents> [https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-documents] no later than 5:00 p.m. Wednesday, April 24, 2024. If both the pre-registration and HHS Form 1320 are not completed and submitted by the due date, members of the public may register on-site the day of the meeting to provide oral comments. Please mark the correct box on the Public Comment Registration form and provide your name, either the organization you are representing or that you are speaking as a private citizen and your direct phone number. If you have completed the Public Comment Registration form, you will receive an email the day before the meeting with instructions for providing virtual public comment. Public comment is limited to three minutes. Each speaker providing oral public comments virtually must ensure their face is visible and their voice audible to the other participants while they are speaking. Each speaker providing oral public comment must state their name and on whose behalf they are speaking (if anyone). If you pre-register to speak and wish to provide a handout before the meeting, please submit an electronic copy in accessible PDF format with a completed Written Public Comment form, HHS Form 1334 at <https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-documents> [https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-documents] , that will be distributed by HHS staff to DURB members and State staff. Handouts are limited to two pages (paper size: 8.5" by 11", one side only). Handouts must be emailed to VDP-Advisory@hhsc.state.tx.us [mailto:VDP-Advisory@hhsc.state.tx.us] immediately after pre-registering, but no later than 5:00 p.m. Monday, April 22, 2024, and include the name of the person who will be commenting. Do not include health or other confidential information in your comments or handouts. Staff will not read aloud handouts aloud during the meeting, but handouts will be provided to DURB members and State staff.
2. **Written comments:** Members of the public may provide written public comments by pre-registering at https://texashhsm meetings.org/DURB_PCReg_Apr2024 [https://texashhsm meetings.org/DURB_PCReg_Apr2024] and completing a Public Comment Registration form, HHS Form 1334 at <https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-documents> [https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-documents] . A member of the public who wishes to provide written public comments must email the comments to VDP-Advisory@hhsc.state.tx.us [mailto:VDP-Advisory@hhsc.state.tx.us] and pre-register no later than 5:00 p.m. Monday, April 22, 2024. Please include your name and the organization you are representing or that you are speaking as a private citizen. Written comments must be emailed to HHSC immediately after pre-registering and include the name of the person who will be commenting. Written comments are limited to ten pages (paper size: 8.5" by 11", one side only). Do not include health or other confidential information in your comments. Staff will not read written comments aloud during the meeting, but comments will be provided to DURB members and State staff.
3. **Oral comments provided in-person at the meeting location:** Members of the public may provide oral public comments during the meeting in person at the meeting location either by pre-registering using the form above or

without pre-registering by completing a form at the entrance to the meeting room. Do not include health or other confidential information in your comments.

Note: These procedures may be revised at the discretion of HHSC.

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services, 512-552-7672, and VDP-Advisory@hhsc.state.tx.us [<mailto:VDP-Advisory@hhsc.state.tx.us>] .

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

Persons who want to attend the meeting and require assistive technology or services should contact Castoreno at 512-552-7672 or VDP-Advisory@hhsc.state.tx.us [<mailto:VDP-Advisory@hhsc.state.tx.us>] at least 72 hours before the meeting so appropriate arrangements can be made.